This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In a study of the effectiveness of a mass immunization campaign in Quebec against meningococcal disease, De Wals et al¹ recently reported on a lack of clinical protection against invasive meningococcal type C infections in children younger than 2 years who were immunized with the polysaccharide meningococcal vaccine. Because of concerns about the efficacy of the vaccine in children younger than 2 years, we evaluated the immunogenicity of this vaccine in children younger than 2 years during the same immunization campaign.

Methods

Patients aged 6 to 24 months, recruited from 9 different public health clinics, were given the bivalent AC polysaccharide meningococcal vaccine (Pasteur Mérieux Connaught, North New York, Ontario). From 6 different lots, each child received 0.5 mL of the vaccine subcutaneously. The research protocol was approved by the Ste-Justine ethics committee and written informed consent was obtained from the parents. Blood samples were obtained before and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Meningococcal Vaccine -- Public Policy and Individual Choices
Offit and Peter
NEJM 2003;349:2353-2356.
FULL TEXT